Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT00054184|
Recruitment Status : Unknown
Verified July 2013 by CTI BioPharma.
Recruitment status was: Active, not recruiting
First Posted : February 6, 2003
Last Update Posted : July 30, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of docetaxel in treating patients who have progressive non-small cell lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: docetaxel Drug: paclitaxel poliglumex||Phase 3|
- Compare the efficacy of polyglutamate paclitaxel (CT-2103) vs docetaxel as second-line therapy, in terms of duration of overall survival, in patients with progressive non-small cell lung cancer.
- Compare the safety and toxicity of these regimens in these patients.
- Compare the disease control (stable disease maintained for at least 12 weeks, partial response, or complete response) and progression-free survival of patients treated with these regimens.
- Compare the improvement in lung cancer symptoms in patients treated with these regimens.
- Compare the frequency of grade 3 and 4 neurotoxicity, edema, alopecia, and side effects related to corticosteroids in patients treated with these regimens.
- Determine the percentage of patients who receive at least 4 courses of study treatment.
- Compare the response rate in patients with measurable disease treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to stage (IV vs other), performance status (0 or 1 vs 2), start of front-line chemotherapy from randomization (less than 16 weeks vs at least 16 weeks), gender, and prior taxane therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes on day 1.
- Arm II: Patients receive docetaxel IV over 1 hour on day 1. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 3 weeks and then every 8 weeks thereafter.
PROJECTED ACCRUAL: A total of 840 patients (420 per treatment arm) will be accrued for this study within 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||350 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study|
|Study Start Date :||January 2003|
|Estimated Primary Completion Date :||December 2013|
|Experimental: Study drug||Drug: docetaxel Drug: paclitaxel poliglumex|
- Saftey [ Time Frame: Baseline to end of treatment ]
- Efficacy [ Time Frame: Basline to EOS ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054184
Hide Study Locations
|United States, Alabama|
|Clinical Research Consultants, Incorporated|
|Hoover, Alabama, United States, 35216|
|United States, Arizona|
|Arizona Clinical Research Center|
|Tucson, Arizona, United States, 85712|
|United States, Arkansas|
|Highlands Oncology Group - Springdale|
|Springdale, Arkansas, United States, 72764|
|United States, California|
|Pacific Cancer Medical Center, Incorporated|
|Anaheim, California, United States, 92801|
|Synergy Hematology/Oncology Medical Associates|
|Encino, California, United States, 91316|
|California Cancer Care, Inc.|
|Greenbrae, California, United States, 94904-2007|
|California Hematology/Oncology Medical Group|
|Torrance, California, United States, 90505|
|United States, Florida|
|Northwest Oncology and Hematology Associates|
|Coral Springs, Florida, United States, 33065|
|Florida Oncology Associates|
|Jacksonville, Florida, United States, 32207|
|Hematology Oncology Associates of theTreasure Coast - Port St. Lucie|
|Port Saint Lucie, Florida, United States, 34952|
|United States, Georgia|
|Snellville, Georgia, United States, 30078-6782|
|United States, Illinois|
|Gross Point Medical Center|
|Skokie, Illinois, United States, 60077|
|United States, Kentucky|
|Western Kentucky Hematology/Oncology Group|
|Paducah, Kentucky, United States, 42003|
|Kentucky Cancer Clinic|
|Pikeville, Kentucky, United States, 41501|
|United States, Missouri|
|Saint Joseph Oncology, Incorporated|
|Saint Joseph, Missouri, United States, 64507|
|United States, Montana|
|Montana Cancer Specialists|
|Missoula, Montana, United States, 59807-7877|
|United States, Nevada|
|Las Vegas Cancer Center|
|Las Vegas, Nevada, United States, 89102|
|United States, New Jersey|
|Howell, New Jersey, United States, 07731|
|Morristown Memorial Hospital|
|Morristown, New Jersey, United States, 07962|
|United States, New Mexico|
|New Mexico Oncology-Hematology Consultants, Limited|
|Albuquerque, New Mexico, United States, 87109|
|United States, New York|
|Queens Medical Associates, PC|
|Fresh Meadows, New York, United States, 11365|
|United States, North Carolina|
|Piedmont Oncology Specialist, II, PLLC|
|Monroe, North Carolina, United States, 28110|
|United States, North Dakota|
|Odyssey Research Services|
|Bismarck, North Dakota, United States, 58501|
|United States, Ohio|
|Gabrail Cancer Center - Canton Office|
|Canton, Ohio, United States, 44718|
|Ireland Cancer Center|
|Cleveland, Ohio, United States, 44106-5065|
|United States, Pennsylvania|
|Pennsylvania Oncology Hematology Associates|
|Philadelphia, Pennsylvania, United States, 19106|
|United States, South Carolina|
|Charleston Hematology-Oncology, P.A.|
|Charleston, South Carolina, United States, 29403|
|Tri County Oncology Associates|
|Rock Hill, South Carolina, United States, 29732-1119|
|Santee Hematology Oncology|
|Sumter, South Carolina, United States, 29150|
|United States, Tennessee|
|Family Cancer Center|
|Collierville, Tennessee, United States, 38017|
|United States, Texas|
|Southwest Regional Cancer Center|
|Austin, Texas, United States, 78705|
|Richardson, Texas, United States, 75080|
|United States, Virginia|
|Danville Hematology and Oncology, Incorporated|
|Danville, Virginia, United States, 24541|
|Virginia Oncology Care P.C.|
|Richlands, Virginia, United States, 24641|
|United States, Washington|
|Western Washington Medical Group|
|Everett, Washington, United States, 98201|
|Study Chair:||Brenda Garrison||PPD, Incorporated|